Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 21, 2020 - Issue 7-8
Submit an article Journal homepage
2,511
Views
9
CrossRef citations to date
0
Altmetric
Clinical & Biomarkers

The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis

Madeline Kelly1 Clinical Translational Medicine, Future Pipeline Discovery, GSK R&D, Hertfordshire, UKORCID Iconhttps://orcid.org/0000-0001-6855-4550View further author information
ORCID Icon,
Arseniy Lavrov2 Clinical Translational Medicine, Future Pipeline Discovery, GSK R&D, Middlesex, UKORCID Iconhttps://orcid.org/0000-0002-2360-2253View further author information
ORCID Icon,
Luis Garcia-Gancedo3 Advanced Biostatistics and Data Analytics CoE, GSK, Hertfordshire, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5631-1711View further author information
ORCID Icon,
Jim Parr4 McLaren Applied Technologies, Surrey, UKORCID Iconhttps://orcid.org/0000-0001-5956-217XView further author information
ORCID Icon,
Robert Hart4 McLaren Applied Technologies, Surrey, UKORCID Iconhttps://orcid.org/0000-0002-8507-3326View further author information
ORCID Icon,
Theresa Chiwera5 United Kingdom Dementia Research Institute, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKORCID Iconhttps://orcid.org/0000-0003-2884-4267View further author information
ORCID Icon,
Christopher E. Shaw5 United Kingdom Dementia Research Institute, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKORCID Iconhttps://orcid.org/0000-0003-0251-0146View further author information
ORCID Icon,
Ammar Al-Chalabi6 Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, UK;7 Department of Neurology, King’s College Hospital, London, UKORCID Iconhttps://orcid.org/0000-0002-4924-7712View further author information
ORCID Icon,
Rachael Marsden8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKORCID Iconhttps://orcid.org/0000-0003-0304-9427View further author information
ORCID Icon,
Martin R. Turner8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKORCID Iconhttps://orcid.org/0000-0003-0267-3180View further author information
ORCID Icon &
Kevin Talbot8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKORCID Iconhttps://orcid.org/0000-0001-5490-1697View further author information
ORCID Icon show all
Pages 563-573 | Received 17 Jan 2020, Accepted 20 May 2020, Published online: 23 Jun 2020

References

  • Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
  • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
  • Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4:605–18.
  • Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014;76:643–57.
  • Food and Drug Administration. Amyotrophic lateral sclerosis: developing drugs for treatment. Guidance for industry [online]. 2019 [accessed 2019 Nov 22]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry
  • Garcia-Gancedo L, Kelly ML, Lavrov A, Parr J, Hart R, Marsden R, et al. Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth. 2019;7:e13433.
  • Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 1 – correlation within subjects. BMJ. 1995;310:446.
  • Tudor-Locke C, Camhi SM, Troiano RP. A catalog of rules, variables, and definitions applied to accelerometer data in the National Health and Nutrition Examination Survey, 2003–2006. Prev Chronic Dis. 2012;9:E113.
  • Tudor-Locke C, Johnson WD, Katzmarzyk PT. U.S. population profile of time-stamped accelerometer outputs: impact of wear time. J Phys Act Health. 2011;8:693–698.
  • Yunusova Y, Graham NL, Shellikeri S, Phuong K, Kulkarni M, Rochon E, et al. Profiling speech and pausing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Plos One. 2016;11:e0147573.
  • Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: a speech subsystem approach. Behav Neurol. 2015;2015:183027.
  • Makkonen T, Ruottinen H, Puhto R, Helminen M, Palmio J. Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms. Int J Lang Commun Disord. 2018;53:385–392.
  • Ferreira MJ, Zanesco A. Heart rate variability as important approach for assessment autonomic modulation. Motriz Rev Educ Fis. 2016;22:3–8.
  • Pavlovic S, Stevic Z, Milovanovic B, Milicic B, Rakocevic-Stojanovic V, Lavrnic D, et al. Impairment of cardiac autonomic control in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:272–276.
  • Andreu-Perez J, Garcia-Gancedo L, McKinnell J, Van der Drift A, Powell A, Hamy V, et. al. Developing fine-grained actigraphies for rheumatoid arthritis patients from a single accelerometer using machine learning. Sensors 2017;17:2113.
  • Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, et al.; NOG112264 Study Group. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208–216.
  • van Eijk RPA, Bakers JNE, Bunte TM, de Fockert AJ, Eijkemans MJC, van den Berg LH, et al. Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. J Neurol. 2019;266:2387–2395.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.